Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | ALL and CLL updates at ASCO 2021

Zaid Abdel Rahman • 1 Jun 2021
ASCO 2021
Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Alemtuzumab Antibodies Blinatumomab Brexucabtagene autoleucel Ibrutinib

Zaid Abdel Rahman, MD, Mayo Clinic, Jacksonville, FL, discusses highlights from the American Society of Clinical Oncology (ASCO) 2021 Virtual meeting, including the results of a study evaluating chemotherapy-free regimens in Philadelphia positive acute lymphoblastic leukemia (ALL), as well as the findings from the ZUMA-3 trial (NCT02614066), also in ALL. In addition, Dr Rahman talks on the results of a study comparing the use of acalabrutinib versus ibrutinib in previously treated patients with chronic lymphocytic leukemia (CLL). This interview was conducted at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Zaid Abdel Rahman

2:48
Ph-like ALL: characteristics, outcomes and role of allo-HCT
Zaid Abdel Rahman • 1 Jun 2021

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals